Claritev Corporation

Claritev Corporation (CTEV) Market Cap

Claritev Corporation has a market capitalization of $387.2M.

Price: $22.71

-0.87 (-3.69%)

Market Cap: 387.16M

NYSE · time unavailable

CEO: Travis S. Dalton

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2020-04-03

Website: https://www.claritev.com

Claritev Corporation (CTEV) - Company Information

Market Cap: 387.16M|Sector: Healthcare

Company Profile

Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.

Analyst Sentiment

92%
Strong Buy

From 6 Active Polls

1Y Forecast: $38.80

▲ +70.8% Potential Upside

Consensus Target Metrics

Low Bound

$28

Median

$37

High Bound

$61

Average

$39

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$38.80
▲ +70.85% Upside
Low Target
$28.00
23% Risk
Median Target
$37.00
63% Mid
High Target
$61.00
169% Max
Consensus
Buy
4 / 5 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)387273703875743336472471471
Enterprise Value ($M)4,9754,8605,3185,4775,3364,9444,9964,9234,965
Price to Earnings Ratio (P/E)-1.31-0.93-2.19-3.14-2.96-1.18-0.86-0.30-0.20
Price/Earnings-to-Growth Ratio (PEG)-9.05-1.73-0.67-1.20
Price to Sales Ratio (P/S)0.401.112.853.563.071.452.032.052.02
Price to Book Ratio (P/B)-1.57-1.13-4.04-8.59-18.6122.645.612.270.78
Price to Free Cash Flow Ratio (P/FCF)-10.78-2.9519.31-53.5220.28-4.87-7.3111.46-67.48
Enterprise Value to Sales (EV/Sales)19.8621.5722.2722.0921.3721.5221.3621.27
Enterprise Value to EBITDA (EV/EBITDA)9.6141.6050.7632.7941.4243.641020.40-21.66-11.99
Debt to Equity Ratio8.87-19.11-26.64-45.69-116.50312.4354.0521.867.53

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CTEV.

gurufocus.com2026-07-30

Claritev Demonstrates Market Leadership as Federal No Surprises Act Disputes Reach Record Levels

Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable, transparent and fair for al

businesswire.com2026-07-30

Claritev Demonstrates Market Leadership as Federal No Surprises Act Disputes Reach Record Levels

MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #HealthcareAffordability--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that, according to newly released 2025 data from the Centers for Medicare & Medicaid Services (CMS), the Company handled more federal Independent Dispute Resolution (IDR) claims than any other non-payer participant. Claritev was the leading independent IDR administrator among all non-p.

prnewswire.com2026-07-28

Claritev™ and SAVVI Financial® Collaborate to Deliver the Next Generation of Healthcare Benefit Decision Support

New solution combines claims-informed intelligence with AI-powered financial guidance to help employees make smarter benefits decisions MCLEAN, Va. and WALTHAM, Mass.

prnewswire.com2026-07-21

Claritev Adopts CodeTogether's AITrax to Bring Greater Measurement and Accountability to AI-Assisted Development

Claritev will use CodeTogether's AITrax to help measure adoption, cost, quality, and value across its enterprise AI-assisted software development initiatives. MCLEAN, Va.

prnewswire.com2026-07-16

Sun Life U.S. and Claritev work to boost efficiency of supplemental health benefits

WELLESLEY, Mass. and MCLEAN, Va., July 16, 2026 /PRNewswire/ -- Sun Life U.S., a leading provider of employee and government benefits, and Claritev, a healthcare technology, data and insights company, are working together to bring more efficiency to supplemental health coverage offered by self-funded employers. Claritev's machine-learning technology helps find diagnosis connections between employees' medical claims and supplemental health coverages – which include critical illness, accident and hospital indemnity – to help covered employees access the benefits they are eligible for.

businesswire.com2026-07-16

Claritev Corporation Announces Second Quarter 2026 Earnings Conference Call

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its second quarter fiscal year 2026 financial results prior to market open on Friday, August 7, 2026, and hold a conference call at 8:00 am Eastern Time.A live webcast of the conference call can be accessed through the Investor Relations sec.

businesswire.com2026-07-09

Claritev Rises to Leader Ranking in Everest Group's 2026 Pre-Payment Integrity Solutions PEAK Matrix® Assessment

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (NYSE: CTEV), a technology, data, and insights company focused on making healthcare more affordable and transparent, today announced it has been recognized as a Leader in the Everest Group Pre-payment Integrity Solutions PEAK Matrix® Assessment 2026. The recognition and ascent into the Leader category reflects Claritev's longstanding history and continued investment in technology-enabled payment integrity that helps health plans identify potent.

businesswire.com2026-06-23

Claritev Corporation Announces Participation in Truist Securities Healthcare Disruptors & Digital Health Conference

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference, including a panel discussion titled “The Data Before the AI: Building the Foundation for Scalable Healthcare Intelligence” with Michael Kim.

gurufocus.com2026-06-03

Claritev Cares and Elizabeth Dole Foundation Team Up to Help Military and Veteran Caregivers Navigate Mental Health Benefits

Claritev Cares, the charitable foundation established by Claritev (NYSE: CTEV), and the Elizabeth Dole Foundation today announced a new collaboration giving mi

businesswire.com2026-06-03

Claritev Cares and Elizabeth Dole Foundation Team Up to Help Military and Veteran Caregivers Navigate Mental Health Benefits

MCLEAN, Va. & WASHINGTON--(BUSINESS WIRE)---- $CTEV #ClaritevCares--Claritev Cares, the charitable foundation established by Claritev (NYSE: CTEV), and the Elizabeth Dole Foundation today announced a new collaboration giving military and veteran caregivers and their families practical guides and resources to navigate their mental health insurance benefits. Developed with Claritev's healthcare subject matter expertise and hosted through the Elizabeth Dole Foundation's trusted caregiver platform, the new web-based guidan.

globenewswire.com2026-06-02

CLARITEV STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating Claritev Corporation on Behalf of Claritev Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Claritev (CTEV) To Contact Him Directly To Discuss Their Options

businesswire.com2026-05-28

CTEV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Claritev Corporation

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Claritev Corporation (“Claritev” or the “Company”) (NYSE:CTEV) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On May 14, 2026, The Capitol Forum reported that the U.S. Department of Justice's anti-trust division has launched a c.

globenewswire.com2026-05-26

CTEV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Claritev Corporation

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Claritev Corporation (“Claritev” or the “Company”) (NYSE:CTEV) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

globenewswire.com2026-05-26

CTEV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Claritev Corporation

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

benzinga.com2026-05-24

The High-Yield Stocks the Smart Money Is Buying Right Now

There is a principle I have followed for 30 years in this business. When the smartest credit team on the planet starts aggressively buying a beaten-down asset class they understand better than anyone alive, you do not sit on your hands and debate whether the timing is perfect.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"CTEV reported Q1’26 revenue of $244.7M, up 0.9% QoQ (vs. $246.6M in Q4’25) and up 5.8% YoY (vs. $231.3M in Q1’25). Net income was -$73.6M (EPS -$4.41), improving vs. -$80.6M in Q4’25 and vs. -$71.3M in Q1’25 (YoY deterioration: net income down ~3.2%; losses widened). Profitability is highly volatile across the last four quarters: operating margin was 2.7% in Q1’26 (vs. 3.5% Q4’25 and 4.2% Q1’25), while net margin remained deeply negative at -30.1%. The primary pressure remains below-the-line items (income before tax -$73.6M) rather than revenue growth itself. Cash flow quality weakened sequentially: operating cash flow was -$45.8M in Q1’26 (vs. +$66.3M in Q4’25), driving free cash flow to -$92.5M. Balance sheet leverage looks strained with total assets $4.84B and negative total equity of about -$234M; long-term debt remains very large (~$4.59B), and cash dropped to ~$21M. Shareholder returns appear muted/negative on momentum: price is $20.59 with only +1.33% 1-year change and no dividend. With no buyback disclosed in Q1’26, total shareholder return looks largely driven by lack of positive price momentum."

Revenue Growth

Neutral

Revenue was $244.7M in Q1’26, up ~0.9% QoQ and ~5.8% YoY, indicating modest underlying topline growth but not an accelerating trend.

Profitability

Neutral

Margins remain weak: net margin was -30.1% in Q1’26, and operating margin eased to 2.7% (vs. 3.5% in Q4’25). Net losses persisted despite positive YoY revenue.

Cash Flow Quality

Neutral

Operating cash flow turned negative in Q1’26 (-$45.8M) after strongly positive Q4’25 (+$66.3M), with free cash flow at -$92.5M. No dividends and limited evidence of shareholder cash returns.

Leverage & Balance Sheet

Neutral

Balance sheet resilience is pressured: total assets ~ $4.84B but total equity is negative (~ -$234M). Long-term debt remains ~ $4.59B and net debt is very high (~$4.59B).

Shareholder Returns

Caution

Stock momentum is not strong (+1.33% 1Y, -63.6% 6M). No dividend disclosed; buybacks not evident in Q1’26, limiting total return.

Analyst Sentiment & Valuation

Neutral

Price target consensus ($32; high $38/low $28) implies potential upside vs. $20.59, but valuation support is undermined by persistent losses, negative equity, and recent cash flow deterioration.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

CTEV delivered a strong Q1 2026 beat with revenue of $244.7M (+5.8% YoY) and adjusted EBITDA of $146.9M (+3.4% YoY) at ~60% margin, alongside record $44.1M ACV bookings toward a $80M-$100M target. Management’s edge is attributed to scaled data rights and workflow automation amplified by AI: provider-contact ID generation cut processing time by >50% and saved >2,000 hours; invoice automation for accounts payable IDR runs thousands of invoices/day with nearly 100% accuracy. Near-term margin pressure appears limited; investment started in Q4 and is expected to be ratable, with stable-to-improving margins in 2H as ACV converts (6-12 month lag). Guidance was raised: revenue to $985M-$1B; full-year adjusted EBITDA held at $605M-$615M (61%-62% margins). Demand headwinds (PSAV volume decline and MA rule changes) were framed as largely offset by acuity/rate mix and minimal quarterly volume impact, keeping the outlook constructive.

AI IconGrowth Catalysts

  • Data iSight (reference-based pricing) outperformed, up 8.4% in Q1 within claims intelligence
  • Higher-acuity outpatient mix drove ~80% of identified savings/revenue in claims analytics (incl. behavioral health)
  • Automation of provider-contact ID (saved >2,000 processing hours) and AI invoice extraction/reconciliation for accounts payable IDR (nearly 100% accuracy, automated 100% daily processing in <1 hour)
  • Services business launch gaining foothold in provider and public sector markets via managed services

Business Development

  • Agreement with GDIT to provide a custom network for the World Trade Center Health Program
  • Signed a relationship with a top-5 health system operating >700 facilities; services include managed services for its EMR, enabled by the Q4 acquisition of OPCG
  • Dallas Scrip added late in 2025 to drive TPA market expansion (AI throughout TPA client life cycle background)

AI IconFinancial Highlights

  • Total revenue: $244.7M, up 5.8% YoY (Q1 outperformed internal expectations)
  • Adjusted EBITDA: $146.9M, up 3.4% YoY at ~60% margin
  • Unlevered free cash flow: $36.8M, up 181% (+$23.7M); free cash flow use: $92.5M (lower by $23.6M vs prior year)
  • Bookings: $44.1M ACV in Q1 toward $80M-$100M full-year target (already ~halfway)
  • Q1 bookings mix: 73% cross-sell/upsell, 27% net new clients; closed 19 deals >$100k ACV and 9 deals >$1M ACV (350% increase in 7-figure deals)
  • Guidance raise: revenue range increased to $985M-$1.0B (bottom end +$5M)
  • Full-year adjusted EBITDA guidance maintained at $605M-$615M with margins of 61%-62%

AI IconCapital Funding

  • Capital budget maintained at $160M-$170M for 2026
  • Positive free cash flow expected; cash conversion expected to normalize to pre-2025 levels by end of year
  • No buyback amounts, new debt levels, or explicit cash runway figures stated in transcript

AI IconStrategy & Ops

  • AI coding tools nearly doubled engineering coding capacity without increased headcount (operating leverage)
  • Expected investment spend ratable quarter-to-quarter after starting in Q4; guidance implies stable-to-slightly improving margins in back half
  • PSAV: modest volume declines in Q1 offset by favorable rate mix; business characterized as more mixed/acuity-driven with growth in complex/higher-cost claims vs more claims volume
  • Utilization: no quarter-to-quarter disruption from weather events; any observed volume softness described as less than expected but savings/revenue per claim strong

AI IconMarket Outlook

  • ACV sales target for 2026: $80M-$100M (20%-50% increase vs prior year); expectation that remaining conversion supports continued strong bookings momentum
  • Full-year revenue: $985M-$1.0B (Q2 expected relatively flat sequentially); second-half growth rate expected at 3%-5%
  • Adjusted EBITDA: $605M-$615M; margins 61%-62%
  • Revenue conversion timing: new bookings take 6-12 months to convert to revenue; ACV ramps expected to drive more in 2H with broader revenue impact in 2027

AI IconRisks & Headwinds

  • PSAV exposure: 8% YoY PSAV claims volume decline referenced by analyst; management states growth driven by acuity/rate mix and AI-driven savings rather than volume
  • Medicare Advantage (MA) final rule: management indicated limited/near-zero quarter-to-quarter volume impact (close to 0 volume impact) despite changes to inpatient determinations and concurrent review cadence
  • Potential demand cyclicality in core: services provide earlier/recurring revenue benefit, implying core seasonality could otherwise affect near-term conversion

Q&A: Analyst Interest

  • Margin drivers: Management explained Q4 began investing to support ACV growth; annualized adjusted OpEx run-rate ~ $385M. They slightly outperformed revenue/EBITDA internally, expect investment to be ratable with ~$1M-$2M quarter swings, and margin stability/slight improvement in 2H as ACV converts.
  • Utilization and rate/mix: Management cited slide-based outpatient/inpatient dynamics: possibly slightly less volume than expected, but strong savings, identified savings/revenue, and savings per claim. Elevated higher-acuity outpatient trends drive ~80% of identified savings/revenue; behavioral health remained consistently strong with no weather-driven disruption indicated.
  • Medicare Advantage and PSAV volume: Management responded that MA could become an opportunity mid/long term but should have limited impact quarter-to-quarter; they expect close to 0 volume impact. For PSAV, they highlighted 8% YoY claims volume decline was expected to be offset by rate mix and AI-enabled savings extraction.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the CTEV Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CTEV.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CTEV)

© 2026 Stock Market Info — Claritev Corporation (CTEV) Financial Profile